Latest Genmab Stories
Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec.
COPENHAGEN, December 1 /PRNewswire/ -- A strong pipeline makes the Copenhagen Region biotech cluster well prepared for the challenges ahead. With 185 drug candidates in preclinical and clinical development, Denmark ranks third in Europe.
Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma.
Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008.
COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK).
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.
COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL).
Genmab, an international biotechnology company, has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma patients in the Phase II study of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone.
COPENHAGEN, September 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
The head of biotech research GlaxoSmithKline Plc said a new generation of "slimline" antibody medicines may be successors to current blockbusters such as Avastin and Rituxan.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.